Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

CN, Harrison; J, Nangalia; R, Boucher; A, Jackson; C, Yap; J, O'Sullivan; S, Fox; I, Ailts; AC, Dueck; HL, Geyer; RA, Mesa; WG, Dunn; E, Nadezhdin; N, Curto-Garcia; A, Green; B, Wilkins; J, Coppell; J, Laurie; M, Garg; J, Ewing; S, Knapper; J, Crowe; F, Chen; I, Koutsavlis; A, Godfrey; S, Arami; M, Drummond; J, Byrne; F, Clark; C, Mead-Harvey; EJ, Baxter; MF, McMullin; AJ, Mead

doi:10.1200/jco.22.01935

Public

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Shared by NobleBlocks on May 1, 2023 • 12:00 AM UTC

Authors:

Harrison CN

Nangalia J

Boucher R

Abstract

Purpose Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms.Patients and methods MAJIC-PV is a randomized phase II trial of ruxolitinib v...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!